Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer-Reference-Cited by-同舟云学术

Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer

Published:2021-01-01 Issue:1 Volume:24 Page:1124-1133
ISSN:1369-6998
Container-title:Journal of Medical Economics
language:en
Short-container-title:Journal of Medical Economics

Author:

Smare Caitlin¹,Dave Kiran¹,Juarez-Garcia Ariadna²,Abraham Pranav³,Penrod John R.³,Camidge D. Ross⁴,Yuan Yong³

Affiliation:

1. HEOR, Parexel International, London, UK

2. Worldwide Health Economics & Outcomes Research, Bristol Myers Squibb, Uxbridge, UK

3. Worldwide Health Economics & Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA

4. Division of Medical Oncology, University of Colorado Denver School of Medicine, Denver, CO, USA

Publisher

Informa UK Limited

Subject

Health Policy

Link

https://www.tandfonline.com/doi/pdf/10.1080/13696998.2021.1974763

Reference45 articles.

1. GLOBOCAN. New global cancer data: GLOBOCAN 2018; 2018. [updated 12 Sept 2018; cited 11 August 2020]; Available from: https://www.uicc.org/new-global-cancer-data-globocan-2018

2. Small Cell Lung Cancer: Have We Made Any Progress Over the Last 25 Years?

3. Progress in the management of limited-stage small cell lung cancer

4. Twenty Years of Phase III Trials for Patients With Extensive-Stage Small-Cell Lung Cancer: Perceptible Progress

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐world data on efficacy/safety and economic impact of nivolumab administered every 2 and 4 weeks among Japanese patients;Asia-Pacific Journal of Clinical Oncology;2024-04-29

2. Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China;Frontiers in Immunology;2023-08-31

3. The poetics of soulful aging;Journal of Religion, Spirituality & Aging;2023-03-15

4. Cost-effectiveness of anlotinib vs. pembrolizumab and nivolumab as third-line treatment in recurrent small cell lung cancer in China;Expert Review of Pharmacoeconomics & Outcomes Research;2022-11-09